Chimeric Therapeutics (ASX:CHM) FCF Yield % : -42.18 (As of May. 17, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Chimeric Therapeutics's Trailing 12-Month Free Cash Flow is A$-8.31 Mil, and Market Cap is A$18.84 Mil. Therefore, Chimeric Therapeutics's FCF Yield % for today is -42.18%.

The historical rank and industry rank for Chimeric Therapeutics's FCF Yield % or its related term are showing as below:

ASX:CHM' s FCF Yield % Range Over the Past 10 Years
Min: -123.77 Med: 0 Max: 0
Current: -42.18

ASX:CHM's FCF Yield % is ranked worse than
72.83% of 1557 companies
in the Biotechnology industry
Industry Median: -14.1 vs ASX:CHM: -42.18

Chimeric Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

Chimeric Therapeutics FCF Yield % Historical Data

The historical data trend for Chimeric Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics FCF Yield % Chart

Chimeric Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

FCF Yield %

-14.74

-34.93

-85.27

Chimeric Therapeutics Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Yield %	Get a 7-Day Free Trial			-15.29	-35.78	-72.51	-37.69	-36.85

Competitive Comparison of Chimeric Therapeutics's FCF Yield %

For the Biotechnology subindustry, Chimeric Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chimeric Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Chimeric Therapeutics's FCF Yield % falls into.

Chimeric Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Chimeric Therapeutics's FCF Yield % for the fiscal year that ended in Jun. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-16.418	/	19.254068
	=	-85.27%

Chimeric Therapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-4.681	*	2	/	25.404435
	=	-36.85%

Chimeric Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Chimeric Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Chimeric Therapeutics (ASX:CHM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

CHMMF:USA

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.chimerictherapeutics.com

Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics (ASX:CHM) Headlines

No Headlines